Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96Q83
UPID:
ALKB3_HUMAN
Alternative names:
Alkylated DNA repair protein alkB homolog 3; DEPC-1; Prostate cancer antigen 1
Alternative UPACC:
Q96Q83; A6NDJ1; Q3SYI0; Q6NX57; Q96BU8
Background:
Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3, also known as Alkylated DNA repair protein alkB homolog 3, DEPC-1, and Prostate cancer antigen 1, plays a crucial role in the repair of alkylated DNA by mediating the demethylation of DNA and RNA containing 1-methyladenosine and 3-methylcytosine. It shows a strong preference for single-stranded DNA and can also act on RNA, demethylating N(1)-methyladenosine in messenger RNAs.
Therapeutic significance:
Understanding the role of Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3 could open doors to potential therapeutic strategies.